Can we be honest?
.....and look for common ground?
ENZC is an exciting company, with a crazy number of cool patents, key industry partnerships and a massive potential future. Clearly, you (and others) feel a bit differently.
But, ENZC is a drug development company. That's not a normal "look at key revenue and P/E rations and determine a price" kind of stock. Any one particular drug being developed has an element of risk; Investors are sort of betting on big things happening, but the probability of that drug being wildly successful is low. With those parameters, it's sometimes hard to price.
ENZC does have some positive mitigating factors, the biggest one is that it's expanding on many fronts. ITV-1, the AI, IPF Immune, monoclonal antibodies, the MS drug (and I probably missed a few).
It's true that the price in Oct 2020 was $0.0001. It's also true that the price was as high as $0.829 (and yes, there was a intra-day trade on that day as high as $0.958) Using $0.08 as the base, the price is up 80,000% from Oct 2020, and down 73% from that closing high (and yes down 87% from that one weird intra-day trade).
Wow, a non-revenue drug development company has volatility. Like that's never happened...sheesh.
Also, a new publicly traded company with a management team who has little public company experience makes a few small mistakes (or ill advised tweets). Again, like THAT's never happened....eyes rolling
The more important issue for investors is: What is the likelihood that one or more of the company's initiatives will be successful? And if so, HOW successful? That is not an issue of the date of the filing of an audit, or a mis-worded PR. It's much larger.
- Is there success in the trials to date on ITV-1?
- Does the market accept IPF Immune?
- Is there outside validation (ie. partnerships) that indicate knowledgeable people think ENZC has something special?
- Are the other drugs/products/partnerships in the pipeline?
THAT is why I am bullish on ENZC!
